SCHEMBL4776613

SCHEMBL4776613

CCNC(=O)c1ccc(NS(=O)(=O)CCc2ccccc2Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
PTGES2 Q9H7Z7 1/20 0.47
EPHX2 P34913 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
NAMPT P43490 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
TRPV1 Q8NER1 1/20 0.44
OPRM1 P35372 2/20 0.43
OPRD1 P41143 2/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MAPT P10636 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777693 0.91 HIF1A (0.54) HIF1ASMN1; SMN2L3MBTL1PTGES2EPHX2
SCHEMBL4770958 0.89 HIF1A (0.52) HIF1ASMN1; SMN2L3MBTL1PTGES2EPHX2
SCHEMBL4768066 0.88 PTGES2 (0.49) HIF1ASMN1; SMN2L3MBTL1PTGES2EPHX2
SCHEMBL4772410 0.87 HIF1A (0.55) HIF1ASMN1; SMN2L3MBTL1PTGES2NAMPT
SCHEMBL4777284 0.85 ACLY (0.49) HIF1ASMN1; SMN2L3MBTL1PTGES2NAMPT
SCHEMBL4774741 0.83 HPGD (0.58) SMN1; SMN2L3MBTL1PTGES2LMNAHPGD
SCHEMBL4771196 0.82 SMN1; SMN2 (0.53) HIF1ASMN1; SMN2L3MBTL1PTGES2NAMPT
SCHEMBL4768011 0.80 ALDH1A1 (0.62) NAMPTLMNACA2
SCHEMBL5571928 0.79 NAMPT (0.45) SMN1; SMN2NAMPTLMNA
SCHEMBL4775200 0.79 L3MBTL1 (0.47) HIF1ASMN1; SMN2L3MBTL1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 HIF1A 4386/4885SMN1; SMN2 1149/4885L3MBTL1 2781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.